Seek Returns logo

LLY vs. XYZ: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at LLY and XYZ, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

SymbolLLYXYZ
Company NameEli Lilly and CompanyBlock, Inc.
CountryUnited StatesUnited States
GICS SectorHealth CareFinancials
GICS IndustryPharmaceuticalsFinancial Services
Market Capitalization658.15 billion USD48.39 billion USD
ExchangeNYSENYSE
Listing DateJune 1, 1972November 19, 2015
Security TypeCommon StockCommon Stock

Historical Performance

This chart compares the performance of LLY and XYZ by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

LLY vs. XYZ: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolLLYXYZ
5-Day Price Return3.43%7.15%
13-Week Price Return1.23%27.74%
26-Week Price Return-15.97%16.15%
52-Week Price Return-22.76%21.10%
Month-to-Date Return-0.80%2.76%
Year-to-Date Return-4.90%-6.59%
10-Day Avg. Volume5.35M6.72M
3-Month Avg. Volume4.49M10.97M
3-Month Volatility41.89%40.23%
Beta0.452.77

Profitability

Return on Equity (TTM)

LLY

88.36%

Pharmaceuticals Industry

Max
38.59%
Q3
19.84%
Median
11.90%
Q1
5.63%
Min
-9.96%

LLY’s Return on Equity of 88.36% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

XYZ

13.95%

Financial Services Industry

Max
40.58%
Q3
20.06%
Median
10.67%
Q1
4.19%
Min
-10.31%

XYZ’s Return on Equity of 13.95% is on par with the norm for the Financial Services industry, indicating its profitability relative to shareholder equity is typical for the sector.

LLY vs. XYZ: A comparison of their Return on Equity (TTM) against their respective Pharmaceuticals and Financial Services industry benchmarks.

Net Profit Margin (TTM)

LLY

25.91%

Pharmaceuticals Industry

Max
34.51%
Q3
17.73%
Median
12.12%
Q1
5.99%
Min
-7.73%

A Net Profit Margin of 25.91% places LLY in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.

XYZ

12.41%

Financial Services Industry

Max
52.86%
Q3
25.58%
Median
12.23%
Q1
6.64%
Min
-9.92%

XYZ’s Net Profit Margin of 12.41% is aligned with the median group of its peers in the Financial Services industry. This indicates its ability to convert revenue into profit is typical for the sector.

LLY vs. XYZ: A comparison of their Net Profit Margin (TTM) against their respective Pharmaceuticals and Financial Services industry benchmarks.

Operating Profit Margin (TTM)

LLY

32.37%

Pharmaceuticals Industry

Max
41.53%
Q3
23.00%
Median
16.24%
Q1
9.24%
Min
-6.94%

An Operating Profit Margin of 32.37% places LLY in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

XYZ

4.82%

Financial Services Industry

Max
77.28%
Q3
37.68%
Median
18.17%
Q1
9.27%
Min
-8.19%

XYZ’s Operating Profit Margin of 4.82% is in the lower quartile for the Financial Services industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.

LLY vs. XYZ: A comparison of their Operating Profit Margin (TTM) against their respective Pharmaceuticals and Financial Services industry benchmarks.

Profitability at a Glance

SymbolLLYXYZ
Return on Equity (TTM)88.36%13.95%
Return on Assets (TTM)16.02%8.08%
Net Profit Margin (TTM)25.91%12.41%
Operating Profit Margin (TTM)32.37%4.82%
Gross Profit Margin (TTM)82.64%39.38%

Financial Strength

Current Ratio (MRQ)

LLY

1.28

Pharmaceuticals Industry

Max
4.49
Q3
2.77
Median
1.74
Q1
1.26
Min
0.11

LLY’s Current Ratio of 1.28 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.

XYZ

1.96

Financial Services Industry

Max
4.58
Q3
2.59
Median
1.33
Q1
0.69
Min
0.01

For the Financial Services industry, the Current Ratio is often not the most suitable measure of short-term liquidity.

LLY vs. XYZ: A comparison of their Current Ratio (MRQ) against their respective Pharmaceuticals and Financial Services industry benchmarks.

Debt-to-Equity Ratio (MRQ)

LLY

2.18

Pharmaceuticals Industry

Max
2.44
Q3
1.07
Median
0.42
Q1
0.11
Min
0.00

LLY’s leverage is in the upper quartile of the Pharmaceuticals industry, with a Debt-to-Equity Ratio of 2.18. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.

XYZ

0.26

Financial Services Industry

Max
4.96
Q3
2.10
Median
0.57
Q1
0.12
Min
0.00

The Debt-to-Equity Ratio is often not the primary focus for assessing leverage in the Financial Services industry.

LLY vs. XYZ: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Pharmaceuticals and Financial Services industry benchmarks.

Interest Coverage Ratio (TTM)

LLY

20.36

Pharmaceuticals Industry

Max
103.95
Q3
44.18
Median
9.83
Q1
2.82
Min
-42.71

LLY’s Interest Coverage Ratio of 20.36 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.

XYZ

12.18

Financial Services Industry

Max
136.23
Q3
56.08
Median
6.55
Q1
2.01
Min
-33.27

The Interest Coverage Ratio is often not a primary indicator of debt servicing capacity in the Financial Services industry.

LLY vs. XYZ: A comparison of their Interest Coverage Ratio (TTM) against their respective Pharmaceuticals and Financial Services industry benchmarks.

Financial Strength at a Glance

SymbolLLYXYZ
Current Ratio (MRQ)1.281.96
Quick Ratio (MRQ)0.531.92
Debt-to-Equity Ratio (MRQ)2.180.26
Interest Coverage Ratio (TTM)20.3612.18

Growth

Revenue Growth

LLY vs. XYZ: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

LLY vs. XYZ: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

LLY

0.77%

Pharmaceuticals Industry

Max
6.98%
Q3
3.32%
Median
2.13%
Q1
0.14%
Min
0.00%

LLY’s Dividend Yield of 0.77% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.

XYZ

0.00%

Financial Services Industry

Max
8.18%
Q3
3.60%
Median
1.56%
Q1
0.00%
Min
0.00%

XYZ currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

LLY vs. XYZ: A comparison of their Dividend Yield (TTM) against their respective Pharmaceuticals and Financial Services industry benchmarks.

Dividend Payout Ratio (TTM)

LLY

36.46%

Pharmaceuticals Industry

Max
165.20%
Q3
90.59%
Median
49.13%
Q1
28.91%
Min
0.00%

LLY’s Dividend Payout Ratio of 36.46% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

XYZ

0.00%

Financial Services Industry

Max
155.56%
Q3
63.71%
Median
18.08%
Q1
0.00%
Min
0.00%

XYZ has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

LLY vs. XYZ: A comparison of their Dividend Payout Ratio (TTM) against their respective Pharmaceuticals and Financial Services industry benchmarks.

Dividend at a Glance

SymbolLLYXYZ
Dividend Yield (TTM)0.77%0.00%
Dividend Payout Ratio (TTM)36.46%0.00%

Valuation

Price-to-Earnings Ratio (TTM)

LLY

47.48

Pharmaceuticals Industry

Max
42.51
Q3
26.88
Median
19.11
Q1
15.12
Min
0.00

At 47.48, LLY’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Pharmaceuticals industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.

XYZ

16.06

Financial Services Industry

Max
63.23
Q3
32.10
Median
14.41
Q1
10.81
Min
0.37

XYZ’s P/E Ratio of 16.06 is within the middle range for the Financial Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

LLY vs. XYZ: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Pharmaceuticals and Financial Services industry benchmarks.

Price-to-Sales Ratio (TTM)

LLY

12.30

Pharmaceuticals Industry

Max
7.55
Q3
4.54
Median
2.11
Q1
1.52
Min
0.00

With a P/S Ratio of 12.30, LLY trades at a valuation that eclipses even the highest in the Pharmaceuticals industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.

XYZ

1.99

Financial Services Industry

Max
11.16
Q3
5.45
Median
2.61
Q1
1.25
Min
0.04

The P/S Ratio is often not a primary valuation tool in the Financial Services industry.

LLY vs. XYZ: A comparison of their Price-to-Sales Ratio (TTM) against their respective Pharmaceuticals and Financial Services industry benchmarks.

Price-to-Book Ratio (MRQ)

LLY

40.43

Pharmaceuticals Industry

Max
9.78
Q3
4.96
Median
2.23
Q1
1.46
Min
0.60

At 40.43, LLY’s P/B Ratio is at an extreme premium to the Pharmaceuticals industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

XYZ

1.89

Financial Services Industry

Max
7.09
Q3
3.79
Median
1.46
Q1
0.83
Min
0.04

XYZ’s P/B Ratio of 1.89 is within the conventional range for the Financial Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

LLY vs. XYZ: A comparison of their Price-to-Book Ratio (MRQ) against their respective Pharmaceuticals and Financial Services industry benchmarks.

Valuation at a Glance

SymbolLLYXYZ
Price-to-Earnings Ratio (TTM)47.4816.06
Price-to-Sales Ratio (TTM)12.301.99
Price-to-Book Ratio (MRQ)40.431.89
Price-to-Free Cash Flow Ratio (TTM)326.0344.30